-              Neutrophils, long considered short-lived immune cells, can be therapeutically targeted when their appropriate subset and functional state are identified for the disease context -              LIfT BioSciences’ immuno-modulatory alpha neutrophils (IMANs) are designed to have the potent anti-tumour activity of naturally occurring N1 neutrophils fixed into their biology London, April 22, 2026 – LIfT BioSciences (‘LIfT’ or ‘the Company’) today announced the publica

- Dr. Bo Rode Hansen, current Board member and Corporate Development Officer named Interim CEO - Alex Blyth, Founder and CEO to step down and will continue to work with the Company at a Board level - LIfT BioSciences is currently advancing its first IMAN-based product and preparing to initiate a first-in-human Phase 1 clinical trial. This groundbreaking next-generation immunotherapy aims to target patients with treatment-resistant cancers. London, January 7, 2026 – LIfT BioS

London, 5 November 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces that preclinical data demonstrating the potential of its first-in-class Immunomodulatory Alpha Neutrophils (IMANs) to restore innate immune competence and remodel the tumour microenvironment (TME) in support of anti-tumor immunity, will be presented in a poster at the 40th Society for Immunotherapy of Cancer bein